BS_CHDGRYHJ
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 115.44021024967148
- age_years
- 3.792
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.457
- G2M_CHECKPOINT+0.415
- OXIDATIVE_PHOSPHORYLATION+0.383
- DNA_REPAIR+0.352
- SPERMATOGENESIS+0.289
- PROTEIN_SECRETION+0.220
- MYC_TARGETS_V2+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.111
- MITOTIC_SPINDLE+0.107
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.536
- INTERFERON_GAMMA_RESPONSE-0.506
- INFLAMMATORY_RESPONSE-0.504
- TNFA_SIGNALING_VIA_NFKB-0.503
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.494
- CHOLESTEROL_HOMEOSTASIS-0.490
- ANGIOGENESIS-0.485
- APICAL_SURFACE-0.481
- IL6_JAK_STAT3_SIGNALING-0.480
- COAGULATION-0.464
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KVNGNETA | medulloblastoma | — | 0.973 |
| 2 | BS_9NJHQE9F | medulloblastoma | — | 0.969 |
| 3 | BS_JFB984RG | medulloblastoma | — | 0.965 |
| 4 | BS_HKZENFDA | medulloblastoma | — | 0.964 |
| 5 | BS_H4B5Y6S0 | medulloblastoma | — | 0.964 |
| 6 | BS_K74PZET7 | medulloblastoma | — | 0.963 |
| 7 | BS_Z7PKVY9J | medulloblastoma | — | 0.963 |
| 8 | BS_KYF0Q0E7 | medulloblastoma | — | 0.957 |
| 9 | BS_HF3RNN2T | medulloblastoma | — | 0.952 |
| 10 | BS_DFWFBYSN | medulloblastoma | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.457 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.415 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.383 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.352 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.289 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.111 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.107 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.007 | Inavolisib | — uncovered |